Baclofen - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for baclofen and what is the scope of freedom to operate?

Baclofen is the generic ingredient in eight branded drugs marketed by Amneal, Heritage, Maia Pharms Inc, Mylan Labs Ltd, Rubicon, Piramal Critical, Metacel Pharms Llc, Ani Pharms, Azurity, Ucb Inc, Andas 5 Holding, Appco, Aurobindo Pharma Ltd, Beximco Pharms Usa, Endo Operations, Eywa, Graviti Pharms, Impax, Ivax Sub Teva Pharms, Lannett Co Inc, Mankind Pharma, Micro Labs, Northstar Hlthcare, Norvium Bioscience, Oxford Pharms, Rising, Sun Pharm Inds Inc, Teva, Unichem, Upsher Smith Labs, Usl Pharma, Watson Labs, Zydus Lifesciences, and Novartis, and is included in forty-eight NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baclofen has fourteen patent family members in eight countries.

There are twenty-one drug master file entries for baclofen. Sixty-four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for baclofen

International Patents:	14
US Patents:	8
Tradenames:	8
Applicants:	34
NDAs:	48
Drug Master File Entries:	21
Finished Product Suppliers / Packagers:	64
Raw Ingredient (Bulk) Api Vendors:	149
Clinical Trials:	126
Patent Applications:	6,925
Drug Prices:	Drug price trends for baclofen
Drug Sales Revenues:	Drug sales revenues for baclofen
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for baclofen
What excipients (inactive ingredients) are in baclofen?	baclofen excipients list
DailyMed Link:	baclofen at DailyMed

See drug prices for baclofen

See drug sales revenues for baclofen

Recent Clinical Trials for baclofen

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospices Civils de Lyon	Phase 2/Phase 3
University of Louisville	Phase 2
Institute of Liver and Biliary Sciences, India	N/A

See all baclofen clinical trials

Generic filers with tentative approvals for BACLOFEN

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	5MG/5ML	SOLUTION;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for baclofen

Drug Class	gamma-Aminobutyric Acid-ergic Agonist
Mechanism of Action	GABA A Agonists GABA B Agonists

Medical Subject Heading (MeSH) Categories for baclofen

GABA-B Receptor Agonists
Muscle Relaxants, Central

Anatomical Therapeutic Chemical (ATC) Classes for baclofen

M03BX	Other centrally acting agents
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for BACLOFEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FLEQSUVY	Oral Suspension	baclofen	25 mg/5 mL	215602	1	2022-05-20
OZOBAX DS	Oral Solution	baclofen	5 mg/5 mL	208193	1	2021-07-26

US Patents and Regulatory Information for baclofen

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norvium Bioscience	BACLOFEN	baclofen	TABLET;ORAL	077121-002	Jul 29, 2005		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Oxford Pharms	BACLOFEN	baclofen	TABLET;ORAL	077088-002	Oct 31, 2007	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Graviti Pharms	BACLOFEN	baclofen	TABLET;ORAL	217788-001	Jan 10, 2024	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for baclofen

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	⤷ Sign Up	⤷ Sign Up
Novartis	LIORESAL	baclofen	TABLET;ORAL	017851-003	Jan 20, 1982	⤷ Sign Up	⤷ Sign Up
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for baclofen

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Canada	3036356	SUSPENSIONS ET DILUANTS POUR LE METRONIDAZOLE ET LE BACLOFENE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN)	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2018049184		⤷ Sign Up
China	109922801	甲硝唑和巴氯芬的混悬剂和稀释剂 (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.